Test Code SQ TESTOS, EPIC LAB2929 Testosterone, Total, Bioavailable, and Free, Serum
Additional Codes
Mayo Test ID |
---|
TTFB |
Reporting Name
Testosterone, Total, Bio, Free, SUseful For
Second- or third-order test for evaluating testosterone status (eg, when abnormalities of sex hormone-binding globulin are present)
Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
TTST | Testosterone, Total, S | Yes | Yes |
FRTST | Testosterone, Free, S | No | Yes |
BATS | Testosterone, Bioavailable, S | No | Yes |
Performing Laboratory

Specimen Type
Serum RedNecessary Information
Patient's age and sex are required.
Specimen Required
Container/Tube: Red top
Specimen Volume: 3.5 mL
Specimen Minimum Volume
2 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Serum Red | Refrigerated (preferred) | 14 days |
Frozen | 60 days |
Reference Values
TESTOSTERONE, TOTAL
Males
0-5 months: 75-400 ng/dL
6 months-9 years: <7-20 ng/dL
10-11 years: <7-130 ng/dL
12-13 years: <7-800 ng/dL
14 years: <7-1,200 ng/dL
15-16 years: 100-1,200 ng/dL
17-18 years: 300-1,200 ng/dL
≥19 years: 240-950 ng/Dl
Tanner Stages*
I (prepubertal): <7-20
II: 8-66
III: 26-800
IV: 85-1,200
V (young adult): 300-950
Females
0-5 months: 20-80 ng/dL
6 months-9 years: <7-20 ng/dL
10-11 years: <7-44 ng/dL
12-16 years: <7-75 ng/dL
17-18 years: 20-75 ng/dL
≥19 years: 8-60 ng/dL
Tanner Stages*
I (prepubertal): <7-20
II: <7-47
III: 17-75
IV: 20-75
V (young adult): 12-60
*Puberty onset (transition from Tanner stage I to Tanner stage II) occurs for boys at a median age of 11.5 (±2) years and for girls at a median age of 10.5 (±2) years. There is evidence that it may occur up to 1 year earlier in obese girls and in African American girls. For boys, there is no definite proven relationship between puberty onset and body weight or ethnic origin. Progression through Tanner stages is variable. Tanner stage V (young adult) should be reached by age 18.
TESTOSTERONE, FREE
Males (adult):
20-<25 years: 5.25-20.7 ng/dL
25-<30 years: 5.05-19.8 ng/dL
30-<35 years: 4.85-19.0 ng/dL
35-<40 years: 4.65-18.1 ng/dL
40-<45 years: 4.46-17.1 ng/dL
45-<50 years: 4.26-16.4 ng/dL
50-<55 years: 4.06-15.6 ng/dL
55-<60 years: 3.87-14.7 ng/dL
60-<65 years: 3.67-13.9 ng/dL
65-<70 years: 3.47-13.0 ng/dL
70-<75 years: 3.28-12.2 ng/dL
75-<80 years: 3.08-11.3 ng/dL
80-<85 years: 2.88-10.5 ng/dL
85-<90 years: 2.69-9.61 ng/dL
90-<95 years: 2.49-8.76 ng/dL
95-100+ years: 2.29-7.91 ng/dL
Males (children):
<1 year: Term infants
1-15 days: 0.20-3.10 ng/dL*
16 days-1 year: Values decrease gradually from newborn (0.20-3.10 ng/dL) to prepubertal levels
*Citation: J Clin Endocrinol Metab 1973;36(6):1132-1142
1-8 years: <0.04-0.11 ng/dL
9 years: <0.04-0.45 ng/dL
10 years: <0.04-1.26 ng/dL
11 years: <0.04-5.52 ng/dL
12 years: <0.04-9.28 ng/dL
13 years: <0.04-12.6 ng/dL
14 years: 0.48-15.3 ng/dL
15 years: 1.62-17.7 ng/dL
16 years: 2.93-19.5 ng/dL
17 years: 4.28-20.9 ng/dL
18 years: 5.40-21.8 ng/dL
19 years: 5.36-21.2 ng/dL
Females (adult):
20-<25 years: 0.06-1.08 ng/dL
25-<30 years: 0.06-1.06 ng/dL
30-<35 years: 0.06-1.03 ng/dL
35-<40 years: 0.06-1.00 ng/dL
40-<45 years: 0.06-0.98 ng/dL
45-<50 years: 0.06-0.95 ng/dL
50-<55 years: 0.06-0.92 ng/dL
55-<60 years: 0.06-0.90 ng/dL
60-<65 years: 0.06-0.87 ng/dL
65-<70 years: 0.06-0.84 ng/dL
70-<75 years: 0.06-0.82 ng/dL
75-<80 years: 0.06-0.79 ng/dL
80-<85 years: 0.06-0.76 ng/dL
85-<90 years: 0.06-0.73 ng/dL
90-<95 years: 0.06-0.71 ng/dL
95-100+ years: 0.06-0.68 ng/dL
Females (children):
<1 year: Term infants
1-15 days: 0.06-0.25 ng/dL*
16 days-1 year: Values decrease gradually from newborn (0.06-0.25 ng/dL) to prepubertal levels
*Citation: J Clin Endocrinol Metab 1973;36(6):1132-1142
1-4 years: <0.04 ng/dL
5 years: <0.04-0.07 ng/dL
6 years: <0.04-0.14 ng/dL
7 years: <0.04-0.23 ng/dL
8 years: <0.04-0.34 ng/dL
9 years: <0.04-0.46 ng/dL
10 years: <0.04-0.59 ng/dL
11 years: <0.04-0.72 ng/dL
12 years: <0.04-0.84 ng/dL
13 years: <0.04-0.96 ng/dL
14 years: <0.04-1.06 ng/dL
15-18 years: <0.04-1.09 ng/dL
19 years: 0.06-1.08 ng/dL
TESTOSTERONE, BIOAVAILABLE
Males
≤19 years: not established
20-29 years: 83-257 ng/dL
30-39 years: 72-235 ng/dL
40-49 years: 61-213 ng/dL
50-59 years: 50-190 ng/dL
60-69 years: 40-168 ng/dL
≥70 years: not established
Females (non-oophorectomized)
≤19 years: not established
20-50 years (on oral estrogen): 0.8-4.0 ng/dL
20-50 years (not on oral estrogen): 0.8-10 ng/dL
>50 Years: not established
Day(s) and Time(s) Performed
Testosterone, bioavailable: Monday through Friday
Testosterone, free: Monday through Saturday, 1 p.m.
Testosterone, total: Monday through Saturday, 1 p.m.
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.CPT Code Information
84402
84403
84410
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
TTFB | Testosterone, Total, Bio, Free, S | 58716-2 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
82978 | Testosterone, Bioavailable, S | 2990-0 |
3631 | Testosterone, Free, S | 2991-8 |
8533 | Testosterone, Total, S | 2986-8 |
Analytic Time
8533: 2 days 3631: 3 days 82978: 2 daysReject Due To
Hemolysis |
Mild OK; Gross reject |
Lipemia |
Mild reject; Gross reject |
Icterus |
Mild OK; Gross reject |
Other |
Serum Gel |
Method Name
FRTST: Equilibrium Dialysis
TTST: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
BATS: Differential Precipitation
Forms
If not ordering electronically, complete, print, and send a General Request (T239) with the specimen.